Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the <scp>UK</scp> : A long‐term cost‐effectiveness analysis based on <scp>SUSTAIN</scp> 11-Reference-Cited by-同舟云学术

Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long‐term cost‐effectiveness analysis based on SUSTAIN 11

Published:2022-11-02 Issue:2 Volume:25 Page:491-500
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Evans Marc¹^ORCID,Chubb Barrie²^ORCID,Malkin Samuel J. P.³^ORCID,Berry Sasha⁴,Lawson Jack²,Hunt Barnaby³^ORCID

Affiliation:

1. Diabetes Resource Centre University Hospital Llandough Cardiff UK

2. Novo Nordisk A/S Søborg Denmark

3. Ossian Health Economics and Communications Basel Switzerland

4. Novo Nordisk Ltd Gatwick UK

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14892

Reference53 articles.

1. Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurements

2. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

3. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials

4. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

5. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes;Diabetology;2023-10-13

3. Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study;Diabetes, Obesity and Metabolism;2023-03-28

4. Impact of BMI and comorbidities on efficacy of once‐weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial;Obesity;2023-03-06